Pharmaceutics (Aug 2024)

Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening

  • Saif-Eldin Abedellatif,
  • Racha Hosni,
  • Andreas Waha,
  • Gerrit H. Gielen,
  • Mohammed Banat,
  • Motaz Hamed,
  • Erdem Güresir,
  • Anne Fröhlich,
  • Judith Sirokay,
  • Anna-Lena Wulf,
  • Glen Kristiansen,
  • Torsten Pietsch,
  • Hartmut Vatter,
  • Michael Hölzel,
  • Matthias Schneider,
  • Marieta Ioana Toma

DOI
https://doi.org/10.3390/pharmaceutics16081042
Journal volume & issue
Vol. 16, no. 8
p. 1042

Abstract

Read online

Background and aims: Brain metastases are prevalent in the late stages of malignant melanoma. Multimodal therapy remains challenging. Patient-derived organoids (PDOs) represent a valuable pre-clinical model, faithfully recapitulating key aspects of the original tumor, including the heterogeneity and the mutational status. This study aimed to establish PDOs from melanoma brain metastases (MBM-PDOs) and to test the feasibility of using them as a model for in vitro targeted-therapy drug testing. Methods: Surgical resection samples from eight patients with melanoma brain metastases were used to establish MBM-PDOs. The samples were enzymatically dissociated followed by seeding into low-attachment plates to generate floating organoids. The MBM-PDOs were characterized genetically, histologically, and immunohistologically and compared with the parental tissue. The MBM-PDO cultures were exposed to dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) followed by a cell viability assessment. Results: Seven out of eight cases were successfully cultivated, maintaining the histological, immunohistological phenotype, and the mutational status of the parental tumors. Five out of seven cases harbored BRAF V600E mutations and were responsive to BRAF and MEK inhibitors in vitro. Two out of seven cases were BRAF wild type: one case harboring an NRAS mutation and the other harboring a KIT mutation, and both were resistant to BRAF and MEK inhibitor therapy. Conclusions: We successfully established PDOs from melanoma brain metastases surgical specimens, which exhibited a consistent histological and mutational profile with the parental tissue. Using FDA-approved BRAF and MEK inhibitors, our data demonstrate the feasibility of employing MBM-PDOs for targeted-therapy in vitro testing.

Keywords